NovaBridge Biosciences
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $161.9M
- Price
- $1.40
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.94%
- Volume
- 379.8K
About
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Quick stats
Shares outstanding115.6M
Computed float64.5M
Float / shares55.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001778016
Websitehttps://www.novabridge.com
AI Summary
AI-generated1/14
minorneutralboard change
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
NovaBridge Biosciences appointed Martin Dewhurst to its Board of Directors as an independent director and a member of both the Audit Committee and the Compensation Committee, effective immediately.
Dewhurst brings more than 30 years of healthcare leadership, including over three decades at McKinsey & Company, where he co-led the Global Life Sciences Practice and co-founded the McKinsey Health Institute. He currently serves on several healthcare boards, including Turn Therapeutics (Nasdaq: TTRX), where he chairs audit or remuneration committees.
The appointment fills the seat of departing independent director Liu Xin, whom the company thanked for her service. This is routine governance housekeeping rather than a strategic or pipeline development.
Red flags
- Appointment fills the seat of departing independent director Liu Xin — a board replacement, not an expansion